In a phase III clinical trial of imatinib‐resistant patients, sunitinib showed improved PFS for GIST patients with KIT exon 11 + 13/14 mutations, while ripretinib provided greater benefits for those with KIT exon 11 + 17/18 mutations [48, 49]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.